Sickle cell disease is a genetic blood disorder that affects approximately 100,000 Americans, with Black Americans accounting for the vast majority of those diagnosed. For most of the history of this disease, treatment options were limited primarily to managing the painful vaso-occlusive crises that define the lived experience of sickle cell, preventing complications with a small number of medications, and bone marrow transplantation for a minority of patients fortunate enough to have a matched sibling donor. The past few years have changed that landscape fundamentally.
Understanding sickle cell disease and its impact
Sickle cell disease results from a mutation in the gene that codes for hemoglobin, the protein in red blood cells responsible for carrying oxygen. The mutated hemoglobin causes red blood cells to assume a rigid, crescent or sickle shape under conditions of low oxygen. These abnormally shaped cells do not move through blood vessels smoothly. They clump together, adhere to vessel walls, and obstruct blood flow, cutting off oxygen to tissues and causing the acute, severe pain episodes known as vaso-occlusive crises.
These crises can affect any part of the body and are notoriously difficult to treat effectively in emergency settings. Research documents that patients with sickle cell disease frequently wait significantly longer than other pain patients to receive pain management in emergency departments, reflecting a broader pattern of inadequate care that has persisted across decades and institutions.
Beyond acute pain crises, sickle cell disease produces cumulative organ damage over a lifetime, affecting the spleen, kidneys, lungs, heart, brain, and eyes. Stroke is a recognized complication that can affect children with the disease. Pulmonary hypertension, chronic kidney disease, and leg ulcers are among the long-term complications that significantly affect quality of life and life expectancy.
The gene therapy breakthrough changing the conversation
Regulatory approval of two gene-based therapies for sickle cell disease in 2023 represented a watershed moment in the history of this disease and in genetic medicine more broadly. Both therapies offer the potential for a functional cure by addressing the genetic root cause of the disease rather than managing its consequences.
One approach uses CRISPR-based gene editing to reactivate fetal hemoglobin production, which does not sickle and which is naturally suppressed after birth. By reactivating this gene, the therapy provides normal-functioning hemoglobin that compensates for the sickled hemoglobin produced by the mutated adult gene. The other approach uses a viral vector to add a corrected copy of the hemoglobin gene directly into the patient’s stem cells.
Both therapies require a one-time treatment process involving the collection of the patient’s stem cells, modification of those cells outside the body, and reinfusion following chemotherapy to make space in the bone marrow. Early trial results showed complete or near-complete elimination of vaso-occlusive crises in the majority of treated patients, representing outcomes previously achievable only through bone marrow transplantation from a matched sibling donor.
What access and equity look like in practice
The transformative potential of gene therapy for sickle cell disease is accompanied by sobering realities about access. The therapies carry price tags in the millions of dollars per treatment, raising profound questions about who will actually benefit from the medical achievement. The infrastructure required to administer these therapies, including specialized stem cell treatment centers, is concentrated in a limited number of urban academic medical centers.
For the patients who cannot yet access gene therapy, hydroxyurea remains the most widely used and evidence-supported conventional treatment for reducing the frequency and severity of pain crises. Newer targeted therapies including voxelotor and crizanlizumab have added additional options for preventing the sickling and vessel adhesion that drive complications, providing meaningful benefit for patients who cannot access or are not yet candidates for gene-based approaches.
